ANGPTL3 (Gene)

Organism:

Homo sapiens

Synonyms:ANG-5, ANGPT5, ANGPTL3, ANL3, ENTREZ:27329, FHBL2, HGNC:491, MIM:604774, NM_014495, NP_055310, angiopoietin like 3

Omim:OMIM:604774

Id:ENSG00000132855

Hgnc:HGNC:491

Entrez:27329

Ensembl:ENSG00000132855

Description:angiopoietin like 3

This gene encodes a member of a family of secreted proteins that function in angiogenesis. The encoded protein, which is expressed predominantly in the liver, is further processed into an N-terminal coiled-coil domain-containing chain and a C-terminal fibrinogen chain. The N-terminal chain is important for lipid metabolism, while the C-terminal chain may be involved in angiogenesis. Mutations in this gene cause familial hypobetalipoproteinemia type 2. [provided by RefSeq, Aug 2015]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ANGPTL3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ANGPTL3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ANGPTL3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ANGPTL3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ANGPTL3.

Results found

Linked to

	Label	Description
	GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228430 FABP5 inhibition Huh-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168596 2 V 3 ADIPONECTIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 3 V 2 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225375 CDK12 CDK13 inhibition 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE220520 3 V 4 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE228430 FABP5 inhibition Huh-7 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE168596 2 V 3 ADIPONECTIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 3 V 2 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE225375 CDK12 CDK13 inhibition 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE220520 3 V 4 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.